Long-term neuro-functional disability in adult patients with community-acquired bacterial meningitis.
Bacterial meningitidis
Cohort study
Functional disability
Neuro-functional disability
Physical disability
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
21
09
2021
accepted:
04
05
2022
pubmed:
4
6
2022
medline:
4
10
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
To investigate the prevalence of neuro-functional disability and its determinants 12 months after community-acquired bacterial meningitis (CABM) in adult patients. In a prospective multicenter cohort study (COMBAT), all consecutive cases of CABM were enrolled and followed up for 12 months. Neuro-functional disability at 12 months was evaluated using a combination of the Glasgow Outcome Scale (functional disability), and the modified Rankin Disability Scale (physical disability). Factors associated with neuro-functional disability were identified by multivariate logistic regression. Among 281 patients, 84 (29.9%) patients exhibited neuro-functional disability at 12 months: 79 (28.1%) with functional disability and 51 (18.1%) with physical disability. Overall, 6 patients (2.1%) died during the follow-up. The most common pathogen identified was Streptococcus pneumoniae (131/272, 48.2%); 77/268 patients (28.7%) had a physical disability at hospital discharge. Factors independently associated with 12-month neuro-functional disability were a pneumococcal meningitis (adjusted OR = 2.8; 95% confidence interval (CI) = [1.3; 6.7]), the presence of a physical disability at hospital discharge (aOR = 2.3; 95%CI = [1.2; 4.4]) and the presence of behavioral disorders at hospital-discharge (aOR = 5.9; 95%CI = [1.6; 28.4]). Dexamethasone use was not significantly associated with neuro-functional disability (OR = 0.2; 95%CI = [< 0.1;1.3]). Neuro-functional disability is frequently reported 12 months after CABM. Detailed neurological examination at discharge is needed to improve the follow-up. NCT01730690.
Identifiants
pubmed: 35657529
doi: 10.1007/s15010-022-01855-2
pii: 10.1007/s15010-022-01855-2
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Banques de données
ClinicalTrials.gov
['NCT01730690']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1363-1372Investigateurs
X Duval
(X)
B Hoen
(B)
B Mourvillier
(B)
E Varon
(E)
S Tubiana
(S)
M C Ploy
(MC)
F Caron
(F)
Pe Bollaert
(P)
O Gaillot
(O)
Mk Taha
(M)
C Poyart
(C)
S Bonacorsi
(S)
F Vandenesch
(F)
E Cambau
(E)
M Lecuit
(M)
A Gravet
(A)
B Frachet
(B)
T De Broucker
(T)
D Levy Bruhl
(D)
F Raffi
(F)
B Abraham
(B)
F Ader
(F)
E Ancel
(E)
N Anguel
(N)
L Argaud
(L)
S Arista
(S)
L Armand-Lefevre
(L)
M N Bachelier
(MN)
S Balavoine
(S)
R Baraduc
(R)
G Barnaud
(G)
G Beraud
(G)
D Bertei
(D)
E Bessede
(E)
T Billard Pomares
(T)
C Biron
(C)
G Blanchard-Marche
(G)
S Bland
(S)
J Boileau
(J)
C Bornstain
(C)
S Bourdon
(S)
A Bousquet
(A)
S Boyer
(S)
A Bozorg-Grayeli
(A)
L Bret
(L)
F Bricaire
(F)
E Brocas
(E)
M Brun
(M)
J Buret
(J)
C Burucoa
(C)
E Cambau
(E)
G Camuset
(G)
C Canevet
(C)
F Caron
(F)
A Carricajo
(A)
I Casin
(I)
D Cassignard
(D)
B Castan
(B)
C Cazanave
(C)
T Challan-Belval
(T)
C Chandesris
(C)
V Chanteperdrix-Marillier
(V)
C Chaplain
(C)
C Charlier-Woerther
(C)
H Chaussade
(H)
C Chirouze
(C)
M Chomarat
(M)
Y E Claessens
(YE)
B Clair
(B)
D Combaux
(D)
J M Conil
(JM)
H Cordel
(H)
P Cormier
(P)
J Cousson
(J)
P Cronier
(P)
E Cua
(E)
V Daneluzzi
(V)
A Dao Dubremetz
(A)
A Defarcy
(A)
N Degand
(N)
S Dekeyser
(S)
D Delaune
(D)
E Denes
(E)
D Descamps
(D)
J L Desmaretz
(JL)
E Devaud
(E)
M C Di Palma
(MC)
S Diamantis
(S)
J L Diehl
(JL)
J Dimet
(J)
A Dinh
(A)
X Duval
(X)
E Descloux
(E)
J Colot
(J)
A Emirian
(A)
O Epaulard
(O)
L Escaut
(L)
C Fabe
(C)
T Ferry
(T)
H Fiette
(H)
C Flateau
(C)
N Fonsale
(N)
E Forestier
(E)
N Fortineau
(N)
T Fraisse
(T)
F Faibis
(F)
M Froidure
(M)
S Gabriel-Solean
(S)
A Gagneux-Brunon
(A)
None Garandeau
M Garcia
(M)
V Garnier
(V)
S Gaudry
(S)
R Ghozzi
(R)
A Gravet
(A)
V Gregoire-Faucher
(V)
M Grosset
(M)
I Gueit
(I)
D Guelon
(D)
C Guillet Caruba
(C)
T Guimard
(T)
Y Guimard
(Y)
J Guinard
(J)
T Hadou
(T)
J P Helene
(JP)
S Henard
(S)
B Henry
(B)
R Hernu
(R)
A C Hochart
(AC)
B Hoen
(B)
N Idri
(N)
G Illes
(G)
X Jacob
(X)
S Jaffuel
(S)
D Jan
(D)
I Jarrin
(I)
F Jaureguy
(F)
C Joseph
(C)
M E Juvin
(ME)
S Kayal
(S)
F Lacassin
(F)
M Lafaurie
(M)
B Lalanne
(B)
I Lamaury
(I)
P Lanotte
(P)
M F Lartigue
(MF)
Y Latorre
(Y)
P Laudat
(P)
E Laurens
(E)
H Laurichesse
(H)
C Le Brun
(C)
V Le Moing
(V)
P Le Turnier
(P)
H Lecuyer
(H)
S Ledru
(S)
L Legout
(L)
C Legrix
(C)
A Lemaignen
(A)
C Lemble
(C)
L Lemee
(L)
S Leotard
(S)
O Lesens
(O)
P Lesprit
(P)
M Levast
(M)
F Louis
(F)
L Quaesaet
(L)
N Luizy
(N)
S Males
(S)
E Malpote
(E)
G Martin-Blondel
(G)
V Martinez
(V)
R Masson
(R)
O Matray
(O)
A Mbadi
(A)
F Mechai
(F)
A Merens
(A)
M C Meyohas
(MC)
G Michel
(G)
A Michon
(A)
J Mootien Yoganaden
(J)
D Morquin
(D)
S Mouly
(S)
N Mrozek
(N)
S Nguyen
(S)
Y Nguyen
(Y)
A Odinotte
(A)
M Ogielska
(M)
E Oziol
(E)
B Page
(B)
E Parisi-Duchene
(E)
T Pasdeloup
(T)
S Patrat-Delon
(S)
I Patry
(I)
A Pechinot
(A)
I Pelloux
(I)
S Picot
(S)
J Pierre
(J)
L Piroth
(L)
C Plassart
(C)
P Plessis
(P)
C Ploton
(C)
M C Ploy
(MC)
L Portel
(L)
M Poupard
(M)
C Poyart
(C)
T Prazuck
(T)
F Raffi
(F)
A Ramanantsoa
(A)
C Rapp
(C)
L Raskine
(L)
J Raymond
(J)
M Revest
(M)
A Riche
(A)
S Robaday-Voisin
(S)
F Robin
(F)
F Roblot
(F)
J P Romaszko
(JP)
F Rousseau
(F)
A L Roux
(AL)
C Royer
(C)
M Saada
(M)
D Salmon
(D)
C Saroufim
(C)
J L Schmit
(JL)
M Sebire
(M)
C Segonds
(C)
F Sifaoui
(F)
V Sivadon-Tardy
(V)
N Soismier
(N)
K Solen
(K)
A Sommabere
(A)
O Son
(O)
J P Stahl
(JP)
R Steux
(R)
S Sunder
(S)
F Suy
(F)
D Tande
(D)
J Tankovic
(J)
S Tigaud
(S)
B Tourrand
(B)
N Valin
(N)
N Van Grunderbeeck
(N)
F Vandenesch
(F)
E Varon
(E)
R Vatan
(R)
C Venot
(C)
M Vergnaud
(M)
None Vernet
M Vidal
(M)
V Vitrat
(V)
D Vittecoq
(D)
F Vuotto
(F)
A Chabrol
(A)
J Cabalion
(J)
Isabelle Gorenne
(I)
Cédric Laouenan
(C)
Estelle Marcault
(E)
France Mentre
(F)
Blandine Pasquet
(B)
Carine Roy
(C)
Sarah F Mentré Tubiana
(SFM)
C Laouenan
(C)
I Gorenne
(I)
E Marcault
(E)
P Manchon
(P)
B Pasquet
(B)
C Roy
(C)
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
van de Beek D, Brouwer MC, Koedel U, Wall EC. Community-acquired bacterial meningitis. The Lancet. 2021;398:1171–83. https://doi.org/10.1016/S0140-6736(21)00883-7 .
doi: 10.1016/S0140-6736(21)00883-7
Bijlsma MW, Brouwer MC, Kasanmoentalib ES, Kloek AT, Lucas MJ, Tanck MW, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis. 2016;16:339–47. https://doi.org/10.1016/S1473-3099(15)00430-2 .
doi: 10.1016/S1473-3099(15)00430-2
pubmed: 26652862
Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. J Infect. 2016;73:18–27. https://doi.org/10.1016/j.jinf.2016.04.009 .
doi: 10.1016/j.jinf.2016.04.009
pubmed: 27105658
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480–4. https://doi.org/10.1016/s0140-6736(75)92830-5 .
doi: 10.1016/s0140-6736(75)92830-5
pubmed: 46957
Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15:573–85. https://doi.org/10.1089/neu.1998.15.573 .
doi: 10.1089/neu.1998.15.573
pubmed: 9726257
Fayol P, Carrière H, Habonimana D, Preux P-M, Dumond J-J. French version of structured interviews for the Glasgow Outcome Scale: guidelines and first studies of validation. Ann Readapt Med Phys. 2004;47:142–56. https://doi.org/10.1016/j.annrmp.2004.01.004 .
doi: 10.1016/j.annrmp.2004.01.004
pubmed: 15130712
Rankin J. Cerebral vascular accidents in patients over the age of 60. II Prognosis Scott Med J. 1957;2:200–15. https://doi.org/10.1177/003693305700200504 .
doi: 10.1177/003693305700200504
pubmed: 13432835
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed) 1988;296:316–20.
des Portes V. Long-term follow-up of bacterial meningitis—sequels in children and adults: incidence, type, and assessment issues. Med Mal Infect. 2009;39:572–80. https://doi.org/10.1016/j.medmal.2009.02.019 .
doi: 10.1016/j.medmal.2009.02.019
pubmed: 19394175
van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849–59. https://doi.org/10.1056/NEJMoa040845 .
doi: 10.1056/NEJMoa040845
pubmed: 15509818
Kastenbauer S, Pfister H-W. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain. 2003;126:1015–25. https://doi.org/10.1093/brain/awg113 .
doi: 10.1093/brain/awg113
pubmed: 12690042
Muralidharan R, Mateen FJ, Rabinstein AA. Outcome of fulminant bacterial meningitis in adult patients. Eur J Neurol. 2014;21:447–53. https://doi.org/10.1111/ene.12328 .
doi: 10.1111/ene.12328
pubmed: 24351087
Tubiana S, Varon E, Biron C, Ploy M-C, Mourvillier B, Taha M-K, et al. Community-acquired bacterial meningitis in adults: in-hospital prognosis, long-term disability and determinants of outcome in a multicentre prospective cohort. Clin Microbiol Infect. 2020;26:1192–200. https://doi.org/10.1016/j.cmi.2019.12.020 .
doi: 10.1016/j.cmi.2019.12.020
pubmed: 31927117
Nguyen THM, Tran THC, Thwaites G, Ly VC, Dinh XS, Ho Dang TN, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med. 2007;357:2431–40. https://doi.org/10.1056/NEJMoa070852 .
doi: 10.1056/NEJMoa070852
pubmed: 18077808
van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62. https://doi.org/10.1016/j.cmi.2016.01.007 .
doi: 10.1016/j.cmi.2016.01.007
pubmed: 27062097
Weir J, Steyerberg EW, Butcher I, Lu J, Lingsma HF, McHugh GS, et al. Does the extended Glasgow Outcome Scale add value to the conventional Glasgow Outcome Scale? J Neurotrauma. 2012;29:53–8. https://doi.org/10.1089/neu.2011.2137 .
doi: 10.1089/neu.2011.2137
pubmed: 22026476
pmcid: 3253309
Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry. 1981;44:285–93. https://doi.org/10.1136/jnnp.44.4.285 .
doi: 10.1136/jnnp.44.4.285
pubmed: 6453957
pmcid: 490949